Replimune Group (REPL) Competitors

Replimune Group logo
$19.69 -1.72 (-8.03%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$19.70 +0.01 (+0.06%)
As of 05:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

REPL vs. RYTM, ALKS, PRAX, ABVX, and KNSA

Should you buy Replimune Group stock or one of its competitors? Replimune Group's main competitors and comparable companies include Rhythm Pharmaceuticals (RYTM), Alkermes (ALKS), Praxis Precision Medicines (PRAX), Abivax (ABVX), and Kiniksa Pharmaceuticals International (KNSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Replimune Group compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Replimune Group (NASDAQ:REPL) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Rhythm Pharmaceuticals has a beta of 2.17, suggesting that its stock price is 117% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Replimune Group has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -69.03%. Replimune Group's return on equity of -157.78% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rhythm Pharmaceuticals-69.03% -171.16% -43.00%
Replimune Group N/A -157.78%-83.89%

In the previous week, Replimune Group had 3 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 8 mentions for Replimune Group and 5 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.78 beat Replimune Group's score of 0.50 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rhythm Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Replimune Group
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rhythm Pharmaceuticals has higher revenue and earnings than Replimune Group. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rhythm Pharmaceuticals$189.76M42.60-$196.54M-$2.90N/A
Replimune GroupN/AN/A-$313.94M-$2.79N/A

92.5% of Replimune Group shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 5.4% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rhythm Pharmaceuticals presently has a consensus price target of $142.00, indicating a potential upside of 21.77%. Replimune Group has a consensus price target of $18.17, indicating a potential downside of 7.74%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Rhythm Pharmaceuticals is more favorable than Replimune Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rhythm Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.77
Replimune Group
2 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Rhythm Pharmaceuticals beats Replimune Group on 9 of the 14 factors compared between the two stocks.

How does Replimune Group compare to Alkermes?

Replimune Group (NASDAQ:REPL) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Replimune Group has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 5.4% of Replimune Group shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Alkermes has higher revenue and earnings than Replimune Group. Alkermes is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Replimune GroupN/AN/A-$313.94M-$2.79N/A
Alkermes$1.48B5.17$241.66M-$0.02N/A

Replimune Group currently has a consensus target price of $18.17, indicating a potential downside of 7.74%. Alkermes has a consensus target price of $55.73, indicating a potential upside of 22.63%. Given Alkermes' stronger consensus rating and higher probable upside, analysts plainly believe Alkermes is more favorable than Replimune Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Replimune Group
2 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50
Alkermes
1 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.65

Replimune Group has a net margin of 0.00% compared to Alkermes' net margin of -0.02%. Alkermes' return on equity of 0.40% beat Replimune Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Replimune GroupN/A -157.78% -83.89%
Alkermes -0.02%0.40%0.19%

In the previous week, Alkermes had 9 more articles in the media than Replimune Group. MarketBeat recorded 17 mentions for Alkermes and 8 mentions for Replimune Group. Alkermes' average media sentiment score of 0.85 beat Replimune Group's score of 0.50 indicating that Alkermes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Replimune Group
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alkermes
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive

Summary

Alkermes beats Replimune Group on 12 of the 15 factors compared between the two stocks.

How does Replimune Group compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Replimune Group (NASDAQ:REPL) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Praxis Precision Medicines has a beta of 2.85, meaning that its share price is 185% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 5.4% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Praxis Precision Medicines has higher revenue and earnings than Replimune Group. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision Medicines$8.55M997.24-$303.27M-$12.80N/A
Replimune GroupN/AN/A-$313.94M-$2.79N/A

Praxis Precision Medicines presently has a consensus price target of $656.42, indicating a potential upside of 115.18%. Replimune Group has a consensus price target of $18.17, indicating a potential downside of 7.74%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Replimune Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Praxis Precision Medicines
2 Sell rating(s)
0 Hold rating(s)
17 Buy rating(s)
3 Strong Buy rating(s)
2.95
Replimune Group
2 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50

Praxis Precision Medicines' return on equity of -29.41% beat Replimune Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Praxis Precision MedicinesN/A -29.41% -28.19%
Replimune Group N/A -157.78%-83.89%

In the previous week, Praxis Precision Medicines had 15 more articles in the media than Replimune Group. MarketBeat recorded 23 mentions for Praxis Precision Medicines and 8 mentions for Replimune Group. Praxis Precision Medicines' average media sentiment score of 0.54 beat Replimune Group's score of 0.50 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Praxis Precision Medicines
5 Very Positive mention(s)
5 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Replimune Group
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Praxis Precision Medicines beats Replimune Group on 11 of the 14 factors compared between the two stocks.

How does Replimune Group compare to Abivax?

Abivax (NASDAQ:ABVX) and Replimune Group (NASDAQ:REPL) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Abivax has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

47.9% of Abivax shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 5.4% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Abivax currently has a consensus target price of $155.00, suggesting a potential upside of 88.79%. Replimune Group has a consensus target price of $18.17, suggesting a potential downside of 7.74%. Given Abivax's stronger consensus rating and higher possible upside, analysts clearly believe Abivax is more favorable than Replimune Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abivax
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88
Replimune Group
2 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Replimune Group had 6 more articles in the media than Abivax. MarketBeat recorded 8 mentions for Replimune Group and 2 mentions for Abivax. Abivax's average media sentiment score of 1.27 beat Replimune Group's score of 0.50 indicating that Abivax is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abivax
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Replimune Group
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Abivax's return on equity of -91.69% beat Replimune Group's return on equity.

Company Net Margins Return on Equity Return on Assets
AbivaxN/A -91.69% -71.96%
Replimune Group N/A -157.78%-83.89%

Abivax is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbivaxN/AN/A-$380.27M-$6.06N/A
Replimune GroupN/AN/A-$313.94M-$2.79N/A

Summary

Abivax beats Replimune Group on 8 of the 13 factors compared between the two stocks.

How does Replimune Group compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Replimune Group (NASDAQ:REPL) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Kiniksa Pharmaceuticals International has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiniksa Pharmaceuticals International$677.56M11.03$59.01M$1.3073.16
Replimune GroupN/AN/A-$313.94M-$2.79N/A

Kiniksa Pharmaceuticals International presently has a consensus price target of $102.38, suggesting a potential upside of 7.64%. Replimune Group has a consensus price target of $18.17, suggesting a potential downside of 7.74%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher probable upside, equities analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Replimune Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiniksa Pharmaceuticals International
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80
Replimune Group
2 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Kiniksa Pharmaceuticals International had 1 more articles in the media than Replimune Group. MarketBeat recorded 9 mentions for Kiniksa Pharmaceuticals International and 8 mentions for Replimune Group. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat Replimune Group's score of 0.50 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kiniksa Pharmaceuticals International
5 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Replimune Group
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kiniksa Pharmaceuticals International has a net margin of 11.58% compared to Replimune Group's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 17.27% beat Replimune Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Kiniksa Pharmaceuticals International11.58% 17.27% 12.64%
Replimune Group N/A -157.78%-83.89%

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 5.4% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Kiniksa Pharmaceuticals International beats Replimune Group on 12 of the 14 factors compared between the two stocks.

Get Replimune Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REPL vs. The Competition

MetricReplimune GroupBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.03B$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.6634.2628.24
Price / SalesN/A15.788.485.70
Price / CashN/A22.9521.0121.90
Price / Book9.124.184.463.72
Net Income-$313.94M-$24.15M$3.52B$393.10M
7 Day Performance-9.60%-7.78%-5.92%-5.76%
1 Month Performance81.31%-5.96%-4.58%-7.14%
1 Year Performance125.29%-8.08%-1.93%-7.46%

Replimune Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REPL
Replimune Group
1.5377 of 5 stars
$19.69
-8.0%
$18.17
-7.7%
+124.5%$2.03BN/AN/A465
RYTM
Rhythm Pharmaceuticals
2.3656 of 5 stars
$109.84
+4.6%
$142.17
+29.4%
+15.8%$7.64B$189.76MN/A414
ALKS
Alkermes
2.7408 of 5 stars
$45.39
+1.9%
$55.06
+21.3%
+55.0%$7.62B$1.75BN/A2,050
PRAX
Praxis Precision Medicines
2.8789 of 5 stars
$272.64
+3.8%
$630.42
+131.2%
+54.4%$7.60BN/AN/A168
ABVX
Abivax
3.2582 of 5 stars
$85.67
+1.8%
$155.00
+80.9%
-27.7%$7.49BN/AN/A80

Related Companies and Tools


This page (NASDAQ:REPL) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners